Hilal Bal
机构：Bilkent University · ORCID：0000-0003-1668-6070
发表论文 14 篇 · 总被引 105 次 · h-index 2
代表论文
- Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer (2018 · Clinical Cancer Research · 被引 67)
- Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer (2024 · Cell Death and Disease · 被引 32)
- Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer (2023 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 2)
- Abstract PS2-11-07: Linc00152-regulated pde4d is a mediator of drug resistance and metastasis in highly aggressive breast cancer (2026 · Clinical Cancer Research)
- Abstract LB019: LINC00152-regulated PDE4D mediates drug resistance and metastasis in highly aggressive breast cancer (2025 · Cancer Research)
- Normal İşiten Bireylerin Konuşma, Uzaysal Algı ve İşitme Kalitelerinin Karşılaştırılması (2025 · KTO Karatay University Institutional Archive)